Quantgene can detect early-stage cancer in a single draw of bloodWhat we are doing is a potential game-changer in medicine. … it makes the detection [of dead cells form tumors] single-molecule precise.
Johannes “Jo” Bhakdi – CEO and Co-Founder of Quantgene
 The FounderIn this interview, we talk to Johannes “Jo” Bhakdi (https://www.linkedin.com/in/jo-bhakdi-5048811/), originally born and raised in the Rhine-Main Area in Germany, but now founder of the AI and Big Data Startup Quantgene (https://www.quantgene.com/, https://www.crunchbase.com/organization/quantgene) in Santa Monica, CA. Quantgene describes itself as a deep genomics startup. They also have an office in Berlin and they hire for both locations.
By training Jo is an economist, who graduated from the University of Tübingen (https://en.wikipedia.org/wiki/University_of_T%C3%BCbingen), a research-heavy university known for its 11 Nobel Laureates in Medicine, Chemistry, and Physics.
Jo started out in advertising and marketing (marketing strategy). He went from there in corporate development, especially mergers and acquisitions. This brought to the USA, first to New York with a stop in venture capital. He was working with his first startup in quantitative seed-stage investments.
What we developed is blood test, that guides physicians in detection of early stage cancer.
Johannes “Jo” Bhakdi – CEO and Co-Founder of Quantgene
 
Affiliate LinksIs your startup in need of a bank account in Germany? Try our partner affiliate Penta http://bit.ly/3bdHX3d
Looking to open a bank account to shift between crypto and fiat? Try our partner Bitwala with this affiliate link here http://bit.ly/2w01Zye 
 
The Startup 
To give you an idea of what we are doing: It is a few megabytes – a simple sequencing of your genome. What we are doing generates files of 200+ Gigabytes
Johannes “Jo” Bhakdi – CEO and Co-Founder of Quantgene
 
Quantgene is a deep tech startup, working with ai, machine learning, and big data to fight cancer. They describe themselves as a deep genome startup. Quantgene is working on unlocking specific hints about cancer in the human genome since cancer is “encoding” itself into the human genome. Quantgene developed a very specific new capability to unlock the human genome of a very deep level. Startups like 23andme generate averages in genome sequencing, a kind of simplification. Quantgene’s approach, on the other hand, is much more specific, but also very complex. They are looking for dead cancer cells – so-called cell-free DNA – in your blood sample. This only works if they are not working with averages but analyze a single copy of DNA in a sample. They had to develop a vast software infrastructure and their own chemistry to make their idea work.
Quantgene also has an office in Berlin, from which Jo joined the Startuprad.io interview. They call it the “Mustererkennungs Einheit” which means the pattern recognition unit.
Quantgene launches in 2020 (as planned before Corona) first in the USA and within some time they want to launch in Germany, Austria, and Switzerland.
 
When you have very early cancer, no one can see, and no one can find – with the current methods. The cancer cells die, and they shed the dead cells into your blood. So they are in your blood as cell free DNA.
Johannes “Jo” Bhakdi – CEO and Co-Founder of Quantgene
 
 
The Video Interview is set to go live on May 7th 19.00 CET(1 pm Eastern, 18.00 London )https://youtu.be/UxghpnCVGSw
 
What Quantgene develop here in the last five years is a very specific capability. We call it the deep human genome.
Johannes “Jo” Bhakdi – CEO and Co-Founder of Quantgene
Venture Capital 
At the time of the interview, Quantgene was raising a note. They are also looking to raise a Series B (all as planned before Corona). https://www.crunchbase.com/organization/quantgene
 
We are roughly 5 years ahea...